 
      CytoDyn Clarifies Status of Biologics License Application
VANCOUVER, Washington, May 08, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications …
 
       
       
       
       
       
       
       
       
       
       
       
       
  
 
     
     
     
     
     
     
     
     
     
     
     
    